New hope for stomach cancer patients with abdominal spread
NCT ID NCT07556640
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of drugs (LM-302, S-1, and intraperitoneal paclitaxel) with or without another drug (cadonilimab) in people with a specific type of advanced stomach cancer (Claudin 18.2-positive) that has spread to the lining of the abdomen. The goal is to see if these treatments improve survival and control the disease. About 74 adults will participate, and the study is currently recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Huangpu District, 200025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?
- Can stomach cancer surgery also tame diabetes?
- Can a modified stomach bypass speed up recovery in advanced gastric cancer?